

Amendments to the Claims

1. (Original) A solid dispersion composition comprising at least 0.1 mg, preferably at least 5 mg, of a sugar ester fatty acid on the basis of an amount equivalent to 100 mg efficacy of cefditoren pivoxil.

2. (Original) The solid dispersion composition according to claim 1, comprising 0.1 mg to 200 mg, preferably at least 5 to 100 mg, more preferably 5 to 50 mg, of the sugar ester fatty acid.

3. (Currently amended) The solid dispersion composition according to claim 1-~~or~~2, which further comprises a pharmaceutically acceptable water-soluble polymer.

4. (Original) The solid dispersion composition according to claim 3, which contains at least 1 mg, preferably 1 to 100 mg, more preferably 1 to 50 mg, of the water-soluble polymer on the basis of an amount equivalent to 100 mg efficacy of cefditoren pivoxil.

5. (Currently amended) The solid dispersion composition according to ~~any one of claims 1 to 4~~ claim 1, which contains 0.1 to 200 mg of the sugar ester fatty acid and 1 to 100 mg of the water-soluble polymer on the basis of an amount equivalent to 100 mg efficacy of cefditoren pivoxil.

6. (Currently amended) The solid dispersion composition according to ~~any one of claims 1 to 4~~ claim 1, which contains 5 to 100 mg of the sugar ester fatty acid and 1 to 50 mg of the water-soluble polymer on the basis of an amount equivalent to 100 mg efficacy of cefditoren pivoxil.

7. (Currently amended) The solid dispersion composition according to ~~any one of claims 3 to 6~~ claim 3, wherein the pharmaceutically acceptable water-soluble polymer is one or more water-soluble polymers selected from the group consisting of

hydroxypropylmethyl cellulose, methylcellulose, hydroxyethyl cellulose, polyvinylpyrrolidone, and hydroxypropyl cellulose.

8. (Currently amended) The solid dispersion composition according to ~~any one of claims 1 to 7~~ claim 1, wherein the amorphousness-maintaining period of cefditoren pivoxil is at least 3 days when suspended in water at a cefditoren pivoxil concentration of 10 mg/ml.

9. (Currently amended) An antibiotic pharmaceutical preparation comprising the composition of ~~any one of claims 1 to 8~~ claim 1 together with a pharmaceutically acceptable additive.

10. (Currently amended) A liquid composition comprising at least 0.1 mg, preferably at least 5 mg, of the sugar ester fatty acid on the basis of an amount equivalent to 100 mg efficacy of cefditoren pivoxil, which is obtainable by dissolving or suspending a solid dispersion composition of ~~any one of claims 1 to 8 or a pharmaceutical preparation of claim 9~~ claim 1 in a medium.

11. (New) A liquid composition comprising at least 0.1 mg, preferably at least 5 mg, of the sugar ester fatty acid on the basis of an amount equivalent to 100 mg efficacy of cefditoren pivoxil, which is obtainable by dissolving or suspending a pharmaceutical preparation of claim 9 in a medium.